Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05035667
  4. Details
NCT05035667 Clinical Trial

Patient Considerations of Social Media Account Management After Death

Advanced Malignant Solid Neoplasm Clinical Trial

Official title:
Social Media Use in Advanced Cancer: Patient Considerations of Social Media Account Management After Death

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05035667
Other study ID # 2019-1171
Secondary ID NCI-2021-0417620
Status Active, not recruiting
Phase
First received
Last updated
Start date December 22, 2020
Est. completion date December 31, 2023

Study information
Verified date October 2023
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. Collecting information on the use of social media and preferences will allow for a better understanding of patient's needs in the dying process and may identify populations in need of education, identify a possible source of anxiety and stress, and allow for an informed discussion of digital legacy.

Description:

PRIMARY OBJECTIVE: I. Identify the proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account (e.g. Facebook, Twitter, Instagram) management after death. SECONDARY OBJECTIVE: I. Identify the proportion of social media participation among advanced cancer patients seen in the supportive care clinic. II. Evaluate the baseline awareness advanced cancer patients seen in the supportive care clinic have regarding how their Facebook account may be managed after death. III. Evaluate affect changes and distress as a result from the conversation regarding their social media account management after death. IV. Evaluate if discussion of social media account management among patients with advanced cancer in the supportive cancer clinic will increase their awareness of and motivation to address their social media account management options. OUTLINE: Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 117
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with at least 1 follow-up visit to the outpatient Supportive Care Clinic at MDACC - Patients with any type of advanced cancer - Patients aged 18 years or older - Patients who have used social media - Patients able to read and write in English Exclusion Criteria: - Delirium as diagnosed by treating Supportive Care Center (SCC) physician or Memorial Delirium Assessment Scale (MDAS) score >= 7

Study Design

Related Conditions & MeSH terms

  • Advanced Malignant Solid Neoplasm
  • Hematopoietic and Lymphoid System Neoplasm
  • Neoplasms

Intervention

Other:
• Questionnaire Administration
Complete questionnaires

Locations
Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)
Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account Will be measured by Question 10 in the survey: "I have had conversations with my family or friends regarding how I would like any of my social media accounts managed after death", which contains five options: Strongly Disagree, Disagree, Neither Agree or Disagree, Agree, or Strongly Agree. The results will be dichotomized into either "Strongly Agree/Agree" or "Neither Agree or Disagree/ Disagree/Strongly Disagree". A two-sided 95% confidence interval will extend a maximum of 0.063 from the proportion of main interest. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Completed NCT02317874 - Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer Phase 1
Recruiting NCT05691491 - Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Phase 1/Phase 2
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Withdrawn NCT03925428 - Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04294628 - Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Phase 1
Active, not recruiting NCT02389309 - Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors Phase 1
Active, not recruiting NCT03065387 - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Phase 1
Terminated NCT04552704 - CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study Phase 1/Phase 2
Active, not recruiting NCT03213691 - Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT05638295 - Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Phase 2
Recruiting NCT05455606 - Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment N/A
Recruiting NCT05101356 - A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma Phase 1/Phase 2
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT02451553 - Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Phase 1
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT01480154 - Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1

External Links